Release of gram-negative outer-membrane proteins into human serum and septic rat blood and their interactions with immunoglobulin in antiserum to Escherichia coli J5

Journal of Infectious Diseases

Volumn 181, Issue 3, 2000, Pages 1034-1043

  Hellman, Judith ^a   Loiselle, Paul M ^a   Zanzot, Emily M ^a,b   Allaire, Jennifer E ^a   Tehan, Megan M ^a   Boyle, Lenora A ^a   Kurnick, James T ^a   Warren, H Shaw ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN; OUTER MEMBRANE PROTEIN;

ARTICLE; BACTERIUM ADHERENCE; ESCHERICHIA COLI; GRAM NEGATIVE SEPSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; STRAIN DIFFERENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; BACTERIAL OUTER MEMBRANE PROTEINS; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN G; MICE; RABBITS; RATS; SEPSIS;

EID: 0034031005     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315302     Document Type: Article

References (61)

1. 1. Chedid L, Parant M, Boyer F. A proposed mechanism for natural immunity to enterobacterial pathogens. J Immunol 1968; 100:292-301.
2. 2. Braude AI, Douglas H, Davis CE. Treatment and prevention of intravascular coagulation with antiserum to endotoxin. J Infect Dis 1973; 128(Suppl): S157-64.
3. 3. McCabe WR, Brums SC, Craven DE, Johns M. Cross-reactive antigens: their potential for immunization-induced immunity to gram-negative bacteria. J Infect Dis 1977; 136(Suppl):S161-6.
4. 4. McCabe WR, DeMaria A, Berberich H, Johns MA. Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant. J Infect Dis 1988; 158:291-300.
5. 5. Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307:1225-30.
6. 6. Baumgartner J, McCutchan JA, Van Melle G, et al. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 1985; 2:59-63.
7. 7. Siber GR, Kania SA, Warren HS. Cross-reactivity of rabbit antibodies to lipopolysaccharides of Escherichia coli J5 and other gram-negative bacteria. J Infect Dis 1985; 152:954-64.
8. 8. Warren HS, Novitsky TJ, Bucklin A, Kania SA, Siber GR. Endotoxin neutralization with rabbit antisera to Escherichia coli J5 and other gram-negative bacteria. Infect Immun 1987; 55:1668-73.
9. 9. Hellman J, Zanzot EM, Loiselle PM, et al. Antiserum against Escherichia coli J5 contains antibodies reactive with outer membrane proteins of heterologous gram-negative bacteria. J Infect Dis 1997; 176:1260-8.
10. 10. Kim KS, Kang JH, Cross AS, Kaufman B, Zollinger W, Sadoff J. Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo. J Infect Dis 1988; 157:47-53.
11. 11 Kohler G, Howe SC, Milstein C. Fusion between immunoglobulin-secreting and non-secreting myeloma cell lines. Eur J Immunol 1976; 6:292-5.
12. 12. Cold Spring Harbor Laboratory. Antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1988.
13. 13. Cryz SJ Jr, Cross AS, Sadoff JC, Furer E. Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines. Infect Immun 1990; 58:373-7.
14. 14. Warren HS, Glennon M, de Deckker FA, Tello D. Role of normal serum in the binding of lipopolysaccharide to IgG fractions from rabbit antisera to Escherichia coli J5 and other gram-negative bacteria. J Infect Dis 1991; 163:1256-66.
15. 15. Ge Y, Ezzell RM, Tompkins RG, Warren HS. Cellular distribution of endotoxin after injection of chemically purified lipopolysaccharide differs from that after injection of live bacteria. J Infect Dis 1994; 169:95-104.
16. 16. Zollinger WD, Boslego JW. A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies. J Immunol Methods 1981; 46:129-40.
17. 17. Stevens EJ, Ryan CM, Friedberg JS, Barnhill RL, Yarmush ML, Tompkins RG. A quantitative model of invasive Pseudomonas infection in burn injury. J Burn Care Rehabil 1994; 15:232-5.
18. 18. Rocque WJ, Coughlin RT, McGroarty EJ. Lipopolysaccharide tightly bound to porin monomers and trimers from Escherichia coli K-12. J Bacteriol 1987; 169:4003-10.
19. 19. Di Padova FE, Brade H, Barclay GR, et al. A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides. Infect Immun 1993; 61:3863-72.
20. 20. Bhattacharjee AK, Opal SM, Taylor R, et al. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis group B outer membrane protein produces protective antibodies against gram-negative bacteremia. J Infect Dis 1996; 173:1157-63.
21. 21. Greisman SE, Johnston CA. Evidence against the hypothesis that antibodies to the inner core of lipopolysaccharides in antisera raised by immunization with enterobacterial deep-rough mutants confer broad-spectrum protection during gram-negative bacterial sepsis. J Endotoxin Res 1997; 4: 123-53.
22. 22. McCallus DE, Norcross NL. Antibody specific for Escherichia coli J5 cross-reacts to various degrees with an Escherichia coli clinical isolate grown for different lengths of time. Infect Immun 1987; 55:1042-6.
23. 23. Tesh VL, Morrison DC. The interaction of Escherichia coli with normal human serum: factors affecting the capacity of serum to mediate lipopolysaccharide release. Microb Pathog 1988; 4:175-87.
24. 24. Flynn PM, Shenep JL, Gigliotti F, Davis DS, Hildner WK. Immunolabeling of lipopolysaccharide liberated from antibiotic-treated Escherichia coli. Infect Immun 1988; 56:2760-2.
25. 25. Van Den Berg C, De Neeling AJ, Schot CS, Hustinz WNM, Wemer J, De Wildt DJ. Delayed antibiotic-induced lysis of Escherichia coli in vitro is correlated with enhancement of LPS release. Scand J Infect Dis 1992; 24: 619-27.
26. 26. Evans ME, Pollack M. Effect of antibiotic class and concentration on the release of lipopolysaccharide from Escherichia coli. J Infect Dis 1993; 167: 1336-43.
27. 27. Johnston CA, Greisman SE. Endotoxemia induced by antibiotic therapy: a mechanism for adrenal corticosteroid protection in gram-negative sepsis. Trans Assoc Am Physicians 1984; 97:172-81.
28. 28. Bucklin SE, Fujihara Y, Leeson MC, Morrison DC. Differential antibiotic-induced release of endotoxin from gram-negative bacteria. Eur J Clin Microbiol Infect Dis 1994; 13(Suppl)1:43-51.
29. 29. Morrison DC, Bucklin SE. Evidence for antibiotic-mediated endotoxin release as a contributing factor to lethality in experimental gram-negative sepsis. Scand J Infect Dis 1996; 101(Suppl):3-8.
30. 30. Munford RS, Hall CL, Rick PD. Size heterogeneity of Salmonella typhimurium lipopolysaccharides in outer membranes and culture supernatant membrane fragments. J Bacteriol 1980; 144:630-40.
31. 31. Hoekstra D, van der Laan JW LLWB. Release of outer membrane fragments from normally growing Escherichia coli. Biochim Biophys Acta 1976; 455: 889-99.
32. 32. Tesh VL, Duncan RL Jr, Morrison DC. The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing. J Immunol 1986; 137:1329-35.
33. 33. Tesh VL, Morrison DC. The physical-chemical characterization and biologic activity of serum released lipopolysaccharides. J Immunol 1988; 141: 3523-31.
34. 34. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE. Endotoxemia in human septic shock. Chest 1991; 99:169-75.
35. 35. Pearson FC, Dubczak J, Weary M, Bruszer G, Donohue G. Detection of endotoxin in the plasma of patients with gram-negative bacterial sepsis by the limulus amoebocyte lysate assay. J Clin Microbiol 1985; 21:865-8.
36. 36. Winchurch RA, Thupari JN, Munster AM. Endotoxemia in burn patients: levels of circulating endotoxins are related to burn size. Surgery 1987; 102:808-12.
37. 37. Wessels BC, Wells MT, Gaffin SL, Brock-Utne JG, Gathiram P, Hinshaw LB. Plasma endotoxin concentration in healthy primates and during E. coli-induced shock. Crit Care Med 1988; 16:601-5.
38. 38. Brandtzaeg P, Oktedalen O, Kierulf P, Opstad PK. Elevated VIP and endotoxin plasma levels in human gram-negative septic shock. Regul Pept 1989; 24:37-44.
39. 39. van Deventer SJH, Buller HR, ten Cate JW, Sturk A, Pauw W. Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet 1988; 1:605-9.
40. 40. Natanson C, Danner RL, Elin RJ, et al. Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J Clin Invest 1989; 83:243-51.
41. 41. Shenep JL, Flynn PM, Barrett FF, Stidham GL, Westenkirchner DF. Serial quantitation of endotoxemia and bacteremia during therapy for gram-negative bacterial sepsis. J Infect Dis 1988; 157:565-8.
42. 42. Munford RS, Hall CL, Lipton JM, Dietschy JM. Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides. J Clin Invest 1982; 70:877-88.
43. 43. Freudenberg MA, Meier-Dieter U, Staehelin T, Galanos C. Analysis of LPS released from Salmonella abortus equi in human serum. Microb Pathog 1992; 10:93-104.
44. 44. Melchers F, Braun V, Galanos C. The lipoprotein of the outer membrane of Escherichia coli: a B-lymphocyte mitogen. J Exp Med 1975; 142:473-82.
45. 45. Doe WF, Yang ST, Morrison DC, Betz SJ, Henson PM. Macrophage stimulation by bacterial lipopolysaccharides. II. Evidence for differentiation signals delivered by lipid A and by a protein rich fraction of lipopolysaccharides. J Exp Med 1978; 148:557-68.
46. 46. Goodman GW, Sultzer BM. Further studies on the activation of lymphocytes by endotoxin protein. J Immunol 1979; 122:1329-34.
47. 47. Goodman GW, Sultzer BM. Characterization of the chemical and physical properties of a novel B-lymphocyte activator, endotoxin protein. Infect Immun 1979; 24:685-96.
48. 48. Chen Y, Hancock R, Mishell R. Mitogenic effects of purified outer membrane proteins from Pseudomonas aeruginosa. Infect Immun 1980; 28:178-84.
49. 49. Goldman RC, White D, Leive L. Identification of outer membrane proteins, including known lymphocyte mitogens, as the endotoxin protein of Escherichia coli O111. J Immunol 1981; 127:1290-4.
50. 50. Galdiero F, Tufano MA, Sommese L, Folgere A, Tedesco F. Activation of complement system by porins extracted from Salmonella typhimurium. Infect Immun 1984; 46:559-63.
51. 51. Bjornson BH, Agura E, Harvey JM, Johns M, Andrews RG, McCabe WR. Endotoxin-associated protein: a potent stimulus for human granulocytopoietic activity which may be accessory cell independent. Infect Immun 1988; 56:1602-7.
52. 52. Johns MA, Sipe JD, Melton LB, Strom TB, McCabe WR. Endotoxin-associated protein: interleukin-1 like activity on serum amyloid A synthesis and T-lymphocyte activation. Infect Immun 1988; 56:1593-601.
53. 53. Hauschildt S, Hoffmann P, Beuscher HU, et al. Activation of bone marrow derived mouse macrophages by bacterial lipopeptide: cytokine production, phagocytosis and la expression. Eur J Immunol 1990; 20:63-8.
54. 54. Porat R, Yanoov M, Johns MA, Shibolet S, Michalevicz R. Effects of endotoxin-associated protein on hematopoiesis. Infect Immun 1992; 60: 1756-60.
55. 55. Mangan DF, Wahl SM, Sultzer BM, Mergenhagen SE. Stimulation of human monocytes by endotoxin-associated protein: inhibition of programmed cell death (apoptosis) and potential significance in adjuvanticity. Infect Immun 1992; 60:1684-6.
56. 56. Galdiero F, Cipollaro de L'Ero G, Benedetto N, Galdiero M, Tufano MA. Release of cytokines induced by Salmonella typhimurium porins. Infect Immun 1993; 61:155-61.
57. c) macrophages. J Immunol 1994; 153:2653-63.
58. 58. Snapper CM, Rosas FR, Jin L, Wortham C, Kehry MR, Mond JJ. Bacterial lipoproteins may substitute for cytokines in the humoral immune response to T cell independent type II antigens. J Immunol 1995; 155:5582-9.
59. 59. Korn A, Rajabi Z, Wassum B, Ruiner W, Nixdorff K. Enhancement of uptake of lipopolysaccharide in macrophages by the major outer membrane protein OmpA of gram-negative bacteria. Infect Immun 1995; 63:2697-705.
60. 60. Zhang H, Peterson JW, Niesel DW, Klimpel GR. Bacterial lipoprotein and lipopolysaccharide act synergistically to induce lethal shock and proinflammatory cytokine production. J Immunol 1997; 159:4868-78.
61. 61. Giambartolomei GH, Dennis VA, Lasater BL, Philipp MT. Induction of pro- and anti-inflammatory cytokines by Borrelia burgdorferi lipoproteins in monocytes is mediated by CD14. Infect Immun 1999; 67:140-7.